
News • Breast Cancer
Biomarker Identified for Likely Aggressive, Early Stage Breast Cancer
The one-size-fits-all approach to early stage breast cancer creates a paradox: Millions of dollars are spent on unnecessary surgeries and radiation to treat women with low-risk ‘in situ’ lesions, an estimated 85% of which would never progress to invasive cancers. Meanwhile, the standard conservative treatment is insufficient for many early-stage tumors that have progressed past the in situ…























